Adial Pharmaceuticals Inc (ADIL NASDAQ) stock market data APIs
$4.0215
0.21(5.2%)
as of September 23, 2026
Try our APIs with
free plan!
Adial Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Prev. Close
4.0215
Open
4.2285
High
4.2515
Low
3.7818
52 wk Range
1.31-10.75
Market Cap
11 852 K
Shares Outstanding
2 934 K
EPS
-11.25
Beta
1.388
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Adial Pharmaceuticals Inc data using free add-ons & libraries
Get Adial Pharmaceuticals Inc Fundamental Data
Adial Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -11 490 897
- Earnings Per Share: -16
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Adial Pharmaceuticals Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.91
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Adial Pharmaceuticals Inc News
New
Adial Acquires Azora With $64 Mln Private Placement; To Advance AT177 For Ulcerative Colitis
(RTTNews) - Adial Pharmaceuticals Inc. (ADIL), a clinical-stage biopharmaceutical company, on Thursday announced the acquisition of Azora Therapeutics Inc. and gained its lead asset AT177, developed f...
Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch...
(RTTNews) - Today's top gainers were led by Australia-based Gelteq, which develops a novel ingestible gel-based drug delivery platform; Adial Pharmaceuticals, which announced the acquisition of Azora ...
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mi...
Get Adial Pharmaceuticals Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
